newsfilter
← Latest News
PR Newswire·

AbbVie Submits Regulatory Application to EMA for SKYRIZI® (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

AbbVie (NYSE: ABBV) today announced that it has submitted an application to the European Medicines Agency (EMA) seeking approval for SKYRIZI®...